BioCentury | Aug 14, 2020
Deals

Data Bytes: Bayer building women’s health portfolio

Bayer’s takeout of KaNDy Therapeutics Ltd. this week is the pharma’s third deal in women’s health this year. In the past decade, the company has closed at least seven R&D, M&A or in-licensing agreements in the...
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return. Private companies working in the space have long struggled to raise venture money. “Women’s health,...
BioCentury | Aug 31, 2018
Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round on Aug. 29. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and...
BioCentury | Aug 29, 2018
Finance

Sweetening the pot

KaNDy Therapeutics Ltd. believes its first venture round as an independent company will fund development of a non-hormonal therapy for menopausal symptoms that will be ready for a Phase III trial by 2020. Longitude Capital...
BioCentury | Aug 29, 2018
Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed in the...
BioCentury | Oct 6, 2017
Company News

NeRRe spins out KaNDy to develop NT-814

NeRRe Therapeutics Ltd. (Stevenage, U.K.) spun out KaNDy Therapeutics Ltd. (Stevenage, U.K.) to develop NT-814 . The candidate has completed Phase IIa testing to treat postmenopausal vasomotor symptoms. NT-814 is a neurokinin 1 receptor ( NK1R ;...
Items per page:
1 - 6 of 6
BioCentury | Aug 14, 2020
Deals

Data Bytes: Bayer building women’s health portfolio

Bayer’s takeout of KaNDy Therapeutics Ltd. this week is the pharma’s third deal in women’s health this year. In the past decade, the company has closed at least seven R&D, M&A or in-licensing agreements in the...
BioCentury | Aug 12, 2020
Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return. Private companies working in the space have long struggled to raise venture money. “Women’s health,...
BioCentury | Aug 31, 2018
Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round on Aug. 29. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and...
BioCentury | Aug 29, 2018
Finance

Sweetening the pot

KaNDy Therapeutics Ltd. believes its first venture round as an independent company will fund development of a non-hormonal therapy for menopausal symptoms that will be ready for a Phase III trial by 2020. Longitude Capital...
BioCentury | Aug 29, 2018
Financial News

Longitude joins syndicate for women's health play KaNDy's £25M series C

KaNDy Therapeutics Ltd. (Stevenage, U.K.) raised £25 million ($31.9 million) in a series C round. New investor Longitude Capital joined existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed in the...
BioCentury | Oct 6, 2017
Company News

NeRRe spins out KaNDy to develop NT-814

NeRRe Therapeutics Ltd. (Stevenage, U.K.) spun out KaNDy Therapeutics Ltd. (Stevenage, U.K.) to develop NT-814 . The candidate has completed Phase IIa testing to treat postmenopausal vasomotor symptoms. NT-814 is a neurokinin 1 receptor ( NK1R ;...
Items per page:
1 - 6 of 6